PPCB News & Events

Propanc Biopharma announced that CEO James Nathanielsz toured a European contract development and manufacturing organization's facility in preparation for the production of the company's lead drug candidate, PRP, ahead of a planned Phase 1b first-in-human clinical study. The schedule developed with the manufacturer includes preproduction in August, an engineering run in October, and active manufacturing starting in December. The company plans to submit a clinical trial application in Australia in 2026 to evaluate the weekly proenzyme therapy in 30 to 40 patients with advanced solid tumors. Nathanielsz said, "Visiting our CDMO partner provides tremendous benefits being able to visualize future cGMP production of PRP, building the foundation for a strong partnership."

Propanc Biopharma announced it has approved a share repurchase program authorizing the company to repurchase up to $5M of its common stock.

Propanc Biopharma announced that a contract and development manufacturing organization, or CDMO, has been engaged for the GMP manufacture of the company's lead asset, PRP, for the upcoming Phase 1b, first-in-human study in 30- 40 advanced cancer patients suffering from solid tumors. Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products.